Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The relatively new concept of quality by design (QbD) in pharmaceutical dosage form design and development, already incorporated
into automakers� production principles, involves designing and developing drug formulations and manufacturing processes
which ensure predefined drug product specifications. An important part of QbD is to understand how process and formulation
variables affect product characteristics and subsequent optimization of these variables vis-� -vis the final specifications. Statistical
design of experiments (DoE) is a well-established method for identifying important parameters in a pharmaceutical dosage form
design and optimizing the parameters with respect to certain specifications; DoE is a valuable tool to establish in mathematical form
the relationships between critical process parameters (CPPs) together with the critical material attributes (CMAs) and critical quality
attributes (CQAs). Further, DoE can help identify optimal conditionsquickly as well as facilitate robustness testing. Approaches
to DoE (to examine all the variables simultaneously) are factorial and mixture experimental designs. When the responses or
nanoparticle properties are known to depend on the proportions of the ingredients, DoE involving mixture methodologyis preferred.
When a formulation is a mixture of various components (proportion of the constituents: macomonomer, crosslinker, stabilizer and
initiator system) as studied in this work and the levels of the components are constrained, D-optimal mixture design is more useful
than a factorial design because it accounts for the dependence of response on proportionality of constituents. Our data on two
nanoparticle systems (fabricated by surfactant-free dispersion polymerization) will be presented: stealth biodegradable palctaxelloaded
polylactide nanoparticles and stealth biodegradable docetaxel-loaded poly-�µ-caprolactone nanoparticles.